Table 4

Summary of bioresorbable coronary scaffolds

NameManufacturerScaffold materialStrut thickness (μm)Time of biodegradationCoatingDrug elutedDrug releaseCompleted clinical studyPrimary endpointOngoing trial
Polylactic acid based scaffolds
BVS V.1.0AbbottPLLA1562 yearsPDLLAEverolimus80% during 30 daysABSORB cohort A (N=30)LLL at 6 M 0.43±0.37 mm
BVS V.1.1AbbottPLLA1562 yearsPDLLAEverolimus80% during 30 daysABSORB cohort B (N=101)LLL at 6 M
0.19±0.18 mm
ABSORB II
(N=501)
RCT of BVS V.1.1 vs Xience
PE: 12 M TLF
ABSORB III
(N=2250)
RCT of BVS V.1.1 vs Xience
PE: 12 M TLF
ABSORB IV
(N=4500–6000)
RCT of BVS V.1.1 vs Xience
PE: TLR between 1 and 5 Y
PRAGUE-19
Registry of BVS V.1.1 in STEMI
ABSORB TROFI-2
(N=196)
RCT BVS V.1.1 vs Xience in STEMI
PE: healing index
DESolveElixir MedicalPLLA1501–2 yearsPLLAMyolimus80% during 30 daysDESolve FIM (N=16)LLL at 6 M 0.19±0.19 mm
NovolimusDESolve Nx (N=126)LLL at 6 M
0.21±0.34 mm
ReZolveREVA MedicalPolycarbonate114–2282 yearsSirolimusRESTORE (N=50)LLL at 12 M
0.20±0.19 mm
(preliminary, N=8)
RESTORE II (N=125)
ReZolve 2 with lower profile
REVA GenREVA MedicalPolycarbonate100–2002 yearsPaclitaxelRESORB (N=27)LLL at 6 M
1.81±0.73mm
IDEALXenogenicsPoly-anhydride ester salicylic acid2009–12 MSalicylateSirolimus>90% during 30 daysWHISPER (N=11)
ART 18ZArterial Remodeling TechnologyPDLLA17018 MARTDIVA (N=30)
Xinsorb BRSHuaan BiotechnologyPLLA, PCL, PLGA160SirolimusXINSORB-FIM
(N=30)
PE: LLL at 6 M
Amaranth BRSAmaranth MedicalPLLA150–2001 year
Metallic scaffolds
AMS-1BiotronikMg alloy165<4 MPROGRESS-AMS (N=63)LLL at 4 M
1.08±0.49 mm
AMS-2BiotronikMg alloy120–130>4 M
DREAMS-1BiotronikMg alloy1259 MPLGAPaclitaxelBIOSOLVE-I (N=46)LLL at 6 M
0.64±0.50 mm
DREAMS-2BiotronikMg alloy1509 MPoly-lactic acidSirolimus
  • FIM, first-in-men; id-TLR, ischaemic driven target lesion revascularisation; LLL, late lumen loss; M, months; Mg, magnesium; NA, not available; PCL, polycaprolactone; PDLLA, poly-D, L-lactic acid; PE, primary end point; PLGA, poly-lactic co-glycolic acid; PLLA, poly-L-lactic acid; RCT, randomised controlled trial; STEMI, ST segment elevation myocardial infarction; TLF, target lesion failure; Y, year.